US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

3.79

+0.20005.57%

Pre-market: 3.72-0.0700-1.85%05:29 EDT

Volume:682.82K

Turnover:2.56M

Market Cap:118.59M

PE:-0.92

High:3.84

Open:3.60

Low:3.60

Close:3.59

52wk High:49.25

52wk Low:3.46

Shares:31.29M

Float Shares:18.39M

Volume Ratio:0.84

T/O Rate:3.71%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.1300

EPS(LYR):-2.8503

ROE:-59.21%

ROA:-37.36%

PB:0.54

PE(LYR):-1.33

Loading ...

Overview Company News Filings

Turn Therapeutics Updates GX-03 Program and Pipeline Outlook

Enliven Therapeutics Reaches Realignment With FDA on Final Design of Relcobatinib's Phase 3 Trial

MT Newswires Live

Valerio Therapeutics accelerates RNA precision pivot with Etherna deal and new CEO

Should New FILSPARI Data Require Action From Travere Therapeutics Stock Investors?

Simply Wall St.

Press Release: Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026

Percheron Therapeutics Wins Strong Shareholder Backing at 2026 AGM

Arovella Therapeutics Says Second Clinical Batch of ALA-101 Manufactured and Released

MT Newswires Live

Nuo Therapeutics Secures Second Loan Funding with Warrants

Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026

Ovid Therapeutics management to meet with B. Riley

Spyre Therapeutics falls -8.4%

Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%

Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026

Guggenheim Initiates Ovid Therapeutics at Buy

MT Newswires Live

Sol-Gel Therapeutics: Buy Rating Reiterated as Pivotal SGT-610 Data Nears; $110 Price Target Maintained

Major Investor Quietly Boosts Stake in Grace Therapeutics

Nexalis Therapeutics director reduces shareholding after loss of beneficiary status

Nexalis Therapeutics Details Director Sean Williams’ Board Exit and Equity Interests

Nexalis Therapeutics appoints Niv Dagan as director with significant equity stake

Spyre Therapeutics 250M share Spot Secondary; re-offered at $85.00

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sgp.itiger.com/stock/LENZ/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":3.79,"timestamp":1791316800000,"preClose":3.59,"halted":0,"volume":682818,"hourTrading":{"tag":"盘前","latestPrice":3.72,"preClose":3.79,"latestTime":"05:29 EDT","volume":22,"amount":81.5199946,"timestamp":1791365389012,"change":-0.07,"changeRate":-0.01847,"amplitude":0.021108},"delay":0,"changeRate":0.05571030640668529,"floatShares":18393300,"shares":31289969,"eps":-4.13,"marketStatus":"Pre-Mkt","change":0.2,"latestTime":"10-07 06:58:05 EDT","open":3.6,"high":3.84,"low":3.6,"amount":2563529.223075,"amplitude":0.066852,"askPrice":3.83,"askSize":1,"bidPrice":3.16,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.13,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791379800000},"marketStatusCode":1,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":3.79,"preHourTrading":{"tag":"盘前","latestPrice":3.72,"preClose":3.79,"latestTime":"05:29 EDT","volume":22,"amount":81.5199946,"timestamp":1791365389012,"change":-0.07,"changeRate":-0.01847,"amplitude":0.021108},"postHourTrading":{"tag":"盘后","latestPrice":3.9,"preClose":3.79,"latestTime":"19:30 EDT","volume":12111,"amount":46011.86,"timestamp":1791329421710,"change":0.11,"changeRate":0.029024,"amplitude":0.029024},"volumeRatio":0.8378969780477704,"impliedVol":2.416,"impliedVolPercentile":0.844},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":18393300,"roa":"-37.36%","roe":"-59.21%","lyrEps":-2.850329,"volumeRatio":0.8378969780477704,"shares":31289969,"dividePrice":0,"high":3.84,"amplitude":0.066852,"preClose":3.59,"low":3.6,"week52Low":3.455,"pbRate":"0.54","psRate":"5.52","week52High":49.25,"institutionHeld":0,"latestPrice":3.79,"committee":0.980198,"eps":-4.13,"divideRate":0,"volume":682818,"delay":0,"ttmEps":-4.13,"open":3.6,"prevYearClose":16,"prevWeekClose":3.58,"prevMonthClose":3.84,"prevQuarterClose":3.84,"fiveDayClose":3.86,"twentyDayClose":5.33,"sixtyDayClose":5.23},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"LENZ","fiscalQuarterEnding":"2026/06","expectedEps":-1.21,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-1.02},{"market":"US","date":"2026-05-11","symbol":"LENZ","fiscalQuarterEnding":"2026/03","expectedEps":-1.1,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-1.32},{"market":"US","date":"2026-03-24","symbol":"LENZ","fiscalQuarterEnding":"2025/12","expectedEps":-0.91,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2026-01-07","symbol":"LENZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1767762000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LENZ","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.59}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.2857,"hold":0.2857,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2857,"analysts":7,"updateTime":1786593600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2026-10-05","current":-0.917676,"percent":1,"low":-26.69966,"twenty":-16.204426,"median":-9.569532,"eighty":-3.694097,"high":-0.892723,"avg":-10.256946,"sd":6.305871,"marketCap":112484827},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-31","current":-15.563946,"twenty":-17.690689,"median":-12.292165,"eighty":-8.168128,"marketCap":815519652},{"date":"2025-11-07","current":-10.439663,"twenty":-17.665927,"median":-12.292165,"eighty":-8.196087,"marketCap":614718687},{"date":"2025-11-14","current":-14.07658,"twenty":-17.595178,"median":-12.325665,"eighty":-8.25011,"marketCap":828871278},{"date":"2025-11-21","current":-14.730193,"twenty":-17.553908,"median":-12.761733,"eighty":-8.286974,"marketCap":867357940},{"date":"2025-11-28","current":-16.218091,"twenty":-17.524554,"median":-12.861347,"eighty":-8.308212,"marketCap":954969853},{"date":"2025-12-05","current":-14.825843,"twenty":-17.466248,"median":-13.119398,"eighty":-8.337771,"marketCap":872990135},{"date":"2025-12-12","current":-13.01911,"twenty":-17.42774,"median":-13.221067,"eighty":-8.354198,"marketCap":766604240},{"date":"2025-12-19","current":-9.070865,"twenty":-17.407695,"median":-13.037789,"eighty":-8.414622,"marketCap":534119770},{"date":"2025-12-26","current":-9.108063,"twenty":-17.390007,"median":-12.866196,"eighty":-8.500376,"marketCap":536310068},{"date":"2026-01-02","current":-8.502276,"twenty":-17.333409,"median":-12.777948,"eighty":-8.502276,"marketCap":500639504},{"date":"2026-01-09","current":-8.098418,"twenty":-17.315721,"median":-12.328345,"eighty":-8.502276,"marketCap":476859127},{"date":"2026-01-16","current":-9.639455,"twenty":-17.280347,"median":-12.249123,"eighty":-8.498134,"marketCap":567600037},{"date":"2026-01-23","current":-11.302713,"twenty":-17.228465,"median":-12.093174,"eighty":-8.501448,"marketCap":665537640},{"date":"2026-01-30","current":-9.448154,"twenty":-17.210778,"median":-11.871572,"eighty":-8.502276,"marketCap":556335648},{"date":"2026-02-06","current":-7.42355,"twenty":-17.195449,"median":-11.633633,"eighty":-8.39709,"marketCap":437120866},{"date":"2026-02-13","current":-6.892157,"twenty":-17.156729,"median":-11.509772,"eighty":-8.290687,"marketCap":405830897},{"date":"2026-02-20","current":-6.403276,"twenty":-17.117721,"median":-11.432889,"eighty":-8.236123,"marketCap":377044126},{"date":"2026-02-27","current":-7.184423,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"marketCap":423040380},{"date":"2026-03-06","current":-6.40859,"twenty":-17.073997,"median":-11.306259,"eighty":-7.995871,"marketCap":377357026},{"date":"2026-03-13","current":-6.281056,"twenty":-17.036729,"median":-11.290275,"eighty":-7.848663,"marketCap":369847433},{"date":"2026-03-20","current":-6.105697,"twenty":-16.999628,"median":-11.252126,"eighty":-7.671592,"marketCap":359521743},{"date":"2026-03-27","current":-3.413108,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"marketCap":280308282},{"date":"2026-04-02","current":-3.569637,"twenty":-16.958959,"median":-11.220775,"eighty":-7.447644,"marketCap":293163583},{"date":"2026-04-10","current":-3.54673,"twenty":-16.933679,"median":-11.193196,"eighty":-7.269441,"marketCap":291282320},{"date":"2026-04-17","current":-3.680353,"twenty":-16.916201,"median":-11.141188,"eighty":-7.181235,"marketCap":302256358},{"date":"2026-04-24","current":-3.493281,"twenty":-16.878888,"median":-11.077981,"eighty":-6.952736,"marketCap":286892705},{"date":"2026-05-01","current":-3.428379,"twenty":-16.817122,"median":-11.044571,"eighty":-6.825202,"marketCap":281562458},{"date":"2026-05-08","current":-3.710895,"twenty":-16.761494,"median":-10.861657,"eighty":-6.578636,"marketCap":304764709},{"date":"2026-05-15","current":-2.097082,"twenty":-16.730518,"median":-10.778852,"eighty":-6.457565,"marketCap":228573532},{"date":"2026-05-22","current":-2.163245,"twenty":-16.709792,"median":-10.723495,"eighty":-6.429023,"marketCap":235785042},{"date":"2026-05-29","current":-2.298448,"twenty":-16.694346,"median":-10.694071,"eighty":-6.404339,"marketCap":250521608},{"date":"2026-06-05","current":-2.071192,"twenty":-16.632408,"median":-10.560046,"eighty":-6.370576,"marketCap":225751636},{"date":"2026-06-12","current":-1.869826,"twenty":-16.608825,"median":-10.439663,"eighty":-6.329861,"marketCap":203803561},{"date":"2026-06-18","current":-1.8238,"twenty":-16.599392,"median":-10.388191,"eighty":-6.238545,"marketCap":198786857},{"date":"2026-06-26","current":-1.585037,"twenty":-16.591349,"median":-10.356288,"eighty":-6.201347,"marketCap":172762710},{"date":"2026-07-02","current":-1.665584,"twenty":-16.562409,"median":-10.323331,"eighty":-6.136275,"marketCap":181541941},{"date":"2026-07-10","current":-1.665584,"twenty":-16.458857,"median":-10.297741,"eighty":-6.098214,"marketCap":181541941},{"date":"2026-07-17","current":-1.403808,"twenty":-16.42504,"median":-10.207556,"eighty":-5.994366,"marketCap":153009442},{"date":"2026-07-24","current":-1.452711,"twenty":-16.399781,"median":-10.175633,"eighty":-5.904593,"marketCap":158339689},{"date":"2026-07-31","current":-1.656954,"twenty":-16.359791,"median":-10.130408,"eighty":-5.831073,"marketCap":180601309},{"date":"2026-08-07","current":-1.501614,"twenty":-16.336075,"median":-10.052902,"eighty":-5.780516,"marketCap":163669936},{"date":"2026-08-14","current":-1.147074,"twenty":-16.332656,"median":-9.910465,"eighty":-5.64279,"marketCap":144533577},{"date":"2026-08-21","current":-1.162036,"twenty":-16.31728,"median":-9.875604,"eighty":-5.484249,"marketCap":146418798},{"date":"2026-08-28","current":-1.19944,"twenty":-16.297238,"median":-9.783769,"eighty":-5.425546,"marketCap":151131849},{"date":"2026-09-04","current":-1.453791,"twenty":-16.251993,"median":-9.763078,"eighty":-5.336455,"marketCap":183180599},{"date":"2026-09-11","current":-1.176997,"twenty":-16.223282,"median":-9.734689,"eighty":-5.236314,"marketCap":148304018},{"date":"2026-09-18","current":-1.029873,"twenty":-16.218091,"median":-9.676907,"eighty":-3.875061,"marketCap":129766016},{"date":"2026-09-25","current":-0.927633,"twenty":-16.212803,"median":-9.639455,"eighty":-3.772744,"marketCap":116883675},{"date":"2026-10-02","current":-0.945089,"twenty":-16.204574,"median":-9.574004,"eighty":-3.700206,"marketCap":119083099},{"date":"2026-10-05","current":-0.892723,"twenty":-16.204426,"median":-9.569532,"eighty":-3.694097,"marketCap":112484827}],"updateTime":1791348049058},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673926060","title":"Turn Therapeutics Updates GX-03 Program and Pipeline Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2673926060","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673926060?lang=en_us&edition=fundamental","pubTime":"2026-10-07 18:33","pubTimestamp":1791369201,"startTime":"0","endTime":"0","summary":"An announcement from Turn Therapeutics Inc ( ($TTRX) ) is now available. On October 6, 2026, Turn Therapeutics Inc. released an updated corporate i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-updates-gx-03-program-and-pipeline-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-updates-gx-03-program-and-pipeline-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007","BK4539","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673709943","title":"Enliven Therapeutics Reaches Realignment With FDA on Final Design of Relcobatinib's Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673709943","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673709943?lang=en_us&edition=fundamental","pubTime":"2026-10-07 17:01","pubTimestamp":1791363707,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics  is on track to start its phase 3 trial of relcobatinib in patients with previously treated chronic myeloid leukemia before the end of 2026, the company said Wednesday.The move comes after the company aligned with the US Food and Drug Administration on the trial's final design.The trial is designed to directly compare relcobatinib with second-generation tyrosine kinase inhibitors and is expected to enroll 450 adults with chronic myeloid leukemia.The primary endpoint is major molecular response at week 24, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4539","BK4139","BK4588","ELVN","LABU","BK4585","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673095666","title":"Valerio Therapeutics accelerates RNA precision pivot with Etherna deal and new CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2673095666","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673095666?lang=en_us&edition=fundamental","pubTime":"2026-10-07 15:08","pubTimestamp":1791356913,"startTime":"0","endTime":"0","summary":"Valerio Therapeutics ( ($FR:ALVIO) ) just unveiled an announcement. Valerio Therapeutics reported that the first half of 2026 was pivotal in its st...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/valerio-therapeutics-accelerates-rna-precision-pivot-with-etherna-deal-and-new-ceo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/valerio-therapeutics-accelerates-rna-precision-pivot-with-etherna-deal-and-new-ceo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673498095","title":"Should New FILSPARI Data Require Action From Travere Therapeutics Stock Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2673498095","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673498095?lang=en_us&edition=fundamental","pubTime":"2026-10-07 14:23","pubTimestamp":1791354237,"startTime":"0","endTime":"0","summary":"Travere Therapeutics reported new FILSPARI data at ASN Kidney Week 2026, with SPARTAN, DUPLEX and PROTECT results underscoring efficacy, renal protection signals and safety in IgA nephropathy and FSGS, alongside real world and molecular findings.\nThe USPTO Notice of Allowance for a new FSGS use patent and an issued IgAN patent extend FILSPARI method-of-use protection into 2037, which matters for Travere Therapeutics’ pricing power, competitive position and long term planning around its lead...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/should-new-filspari-data-require-action-from-travere-therape","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/should-new-filspari-data-require-action-from-travere-therape","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","ISBC","LENZ","TVTX","FFTY","BK4139","BK4539","BK4007","LU2324357040.USD","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673009802","title":"Press Release: Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673009802","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673009802?lang=en_us&edition=fundamental","pubTime":"2026-10-07 14:21","pubTimestamp":1791354060,"startTime":"0","endTime":"0","summary":"--  Operational launch of InVimmune, a subsidiary dedicated to. differentiated approaches to in vivo cell therapy, with a first. --  Appointment of Gilles Besin as Chief Executive Officer, effective July. --  Signing of a binding term sheet with Abivax with a view to an exclusive. --  Achievement of a major strategic milestone with the acquisition of. Etherna Immunotherapies NV; the transaction is expected to be finalised. --  Cash and cash equivalents totaling EUR656,000 as at 30 June 2026. As of. the date of the half-year financier report, the cash position covers 12","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673306057","title":"Percheron Therapeutics Wins Strong Shareholder Backing at 2026 AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2673306057","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673306057?lang=en_us&edition=fundamental","pubTime":"2026-10-07 12:57","pubTimestamp":1791349038,"startTime":"0","endTime":"0","summary":"Percheron Therapeutics ( ($AU:PER) ) has issued an update. Percheron Therapeutics Limited has reported the outcomes of its 2026 Annual General Meet...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/percheron-therapeutics-wins-strong-shareholder-backing-at-2026-agm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/percheron-therapeutics-wins-strong-shareholder-backing-at-2026-agm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673062351","title":"Arovella Therapeutics Says Second Clinical Batch of ALA-101 Manufactured and Released","url":"https://stock-news.laohu8.com/highlight/detail?id=2673062351","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673062351?lang=en_us&edition=fundamental","pubTime":"2026-10-07 10:29","pubTimestamp":1791340181,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics  said a second clinical batch of ALA-101, its cell therapy for blood cancers, has been manufactured and released, according to a Wednesday filing on the Australian bourse.The company added that a third batch, which it expects to release by the end of December, is anticipated to provide enough material to complete the phase 1 trial of 46 patients across five hospital sites.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LABX","BK4139","BK4539","LENZ","BK7096","ALA","ALA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673706503","title":"Nuo Therapeutics Secures Second Loan Funding with Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2673706503","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673706503?lang=en_us&edition=fundamental","pubTime":"2026-10-07 05:18","pubTimestamp":1791321514,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Nuo Therapeutics ( ($AURX) ). On October 6, 2026, Nuo Therapeutics, Inc. completed the second funding under its...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nuo-therapeutics-secures-second-loan-funding-with-warrants?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nuo-therapeutics-secures-second-loan-funding-with-warrants?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4007","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673063976","title":"Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673063976","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673063976?lang=en_us&edition=fundamental","pubTime":"2026-10-07 04:05","pubTimestamp":1791317100,"startTime":"0","endTime":"0","summary":"Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated kidney disease Two poster presentations will highlight preclinical research support","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/06/3376001/0/en/maze-therapeutics-to-present-data-from-mze829-and-mze782-programs-at-asn-kidney-week-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673794057","title":"Ovid Therapeutics management to meet with B. Riley","url":"https://stock-news.laohu8.com/highlight/detail?id=2673794057","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673794057?lang=en_us&edition=fundamental","pubTime":"2026-10-07 00:10","pubTimestamp":1791303019,"startTime":"0","endTime":"0","summary":"Meeting to be held in Los Angeles on October 14 hosted by B. Riley. Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ovid-therapeutics-management-to-meet-with-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ovid-therapeutics-management-to-meet-with-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673542070","title":"Spyre Therapeutics falls -8.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673542070","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673542070?lang=en_us&edition=fundamental","pubTime":"2026-10-06 22:07","pubTimestamp":1791295626,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) is down -8.4%, or -$7.80 to $84.92. Published first on TheFly – the ultimate source for real-time, market-moving breaking...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-falls-8-4-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-falls-8-4-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE","LENZ","BK4139","BK4007","BK4539","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673056656","title":"Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673056656","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673056656?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:00","pubTimestamp":1791288000,"startTime":"0","endTime":"0","summary":"Company secures new formulary coverage with a major Pharmacy Benefit Manager, reaching an additional 24 million covered lives Pelthos gains enhanced commercial coverage through a regional commercial h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/06/3375451/0/en/pelthos-therapeutics-announces-expanded-formulary-coverage-for-zelsuvmi-berdazimer-topical-gel-10-3.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673056630","title":"Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673056630","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673056630?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:00","pubTimestamp":1791288000,"startTime":"0","endTime":"0","summary":"NORCROSS, Ga., Oct.  06, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/06/3375397/27423/en/galectin-therapeutics-to-present-at-the-american-association-for-the-study-of-liver-diseases-aasld-liver-meeting-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4117","GALT","BK4139","BK4539","BK4007","AFG","BK4107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673555540","title":"Guggenheim Initiates Ovid Therapeutics at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2673555540","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673555540?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:25","pubTimestamp":1791285932,"startTime":"0","endTime":"0","summary":"Ovid Therapeutics (OVID) has an average rating of buy and mean price target of $6.11, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4539","OVID","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673534670","title":"Sol-Gel Therapeutics: Buy Rating Reiterated as Pivotal SGT-610 Data Nears; $110 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2673534670","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673534670?lang=en_us&edition=fundamental","pubTime":"2026-10-06 18:56","pubTimestamp":1791284210,"startTime":"0","endTime":"0","summary":"Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Sol-Gel Technologies and keeping the price target at $110.00. Ram Selvaraju h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/sol-gel-therapeutics-buy-rating-reiterated-as-pivotal-sgt-610-data-nears-110-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/sol-gel-therapeutics-buy-rating-reiterated-as-pivotal-sgt-610-data-nears-110-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673033349","title":"Major Investor Quietly Boosts Stake in Grace Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2673033349","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673033349?lang=en_us&edition=fundamental","pubTime":"2026-10-06 10:01","pubTimestamp":1791252073,"startTime":"0","endTime":"0","summary":"New insider activity at Grace Therapeutics ( ($GRCE) ) has taken place on October 5, 2026. Significant shareholder Opaleye Management Inc. has incr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-boosts-stake-in-grace-therapeutics-insider-trading-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-boosts-stake-in-grace-therapeutics-insider-trading-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673403826","title":"Nexalis Therapeutics director reduces shareholding after loss of beneficiary status","url":"https://stock-news.laohu8.com/highlight/detail?id=2673403826","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673403826?lang=en_us&edition=fundamental","pubTime":"2026-10-06 09:57","pubTimestamp":1791251835,"startTime":"0","endTime":"0","summary":"InhaleRx Limited ( ($AU:NX1) ) has issued an announcement. Nexalis Therapeutics has reported a significant change in director Darryl Davies’ releva...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nexalis-therapeutics-director-reduces-shareholding-after-loss-of-beneficiary-status?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nexalis-therapeutics-director-reduces-shareholding-after-loss-of-beneficiary-status?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673385650","title":"Nexalis Therapeutics Details Director Sean Williams’ Board Exit and Equity Interests","url":"https://stock-news.laohu8.com/highlight/detail?id=2673385650","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673385650?lang=en_us&edition=fundamental","pubTime":"2026-10-06 09:17","pubTimestamp":1791249443,"startTime":"0","endTime":"0","summary":"An update from InhaleRx Limited ( ($AU:NX1) ) is now available. Nexalis Therapeutics has disclosed that director Sean Williams ceased serving on th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nexalis-therapeutics-details-director-sean-williams-board-exit-and-equity-interests?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nexalis-therapeutics-details-director-sean-williams-board-exit-and-equity-interests?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2237443978.SGD","IE00BMG7P702.HKD","VDE","MLPI","IVEP","EQR","IE00BLSP4452.SGD","EINC","MDST","DIG","IE00BBT3K403.USD","LU0208291251.USD","NVIR","IE00BN8TJ469.HKD","GXPE","LU1621768206.USD","ENFR","XLE","LU0266512473.USD","FENY","LU0345780950.USD","REZ","USAI","LU0368265418.SGD","TRUN","WEEI","LU2237443895.HKD","LU2237443549.SGD","IE000HOSIQF4.USD","LU0345781412.USD","BK4585","BK4007","IYE","TPYP","LU2237443465.HKD","TEXU","RSPG","USNG","IE00BMG7P694.USD","LU0456854461.SGD","LU0630314457.HKD","IE000WXP2NQ0.USD","LU2384288077.EUR","BESF","TPZ","LENZ","WMB","MLPX","UMI","IE00BD4GTT62.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673038573","title":"Nexalis Therapeutics appoints Niv Dagan as director with significant equity stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2673038573","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673038573?lang=en_us&edition=fundamental","pubTime":"2026-10-06 09:17","pubTimestamp":1791249434,"startTime":"0","endTime":"0","summary":"The latest announcement is out from InhaleRx Limited ( ($AU:NX1) ). Nexalis Therapeutics Ltd has appointed Niv Dagan as a director, with the appoin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nexalis-therapeutics-appoints-niv-dagan-as-director-with-significant-equity-stake?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nexalis-therapeutics-appoints-niv-dagan-as-director-with-significant-equity-stake?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673082920","title":"Spyre Therapeutics 250M share Spot Secondary; re-offered at $85.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2673082920","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673082920?lang=en_us&edition=fundamental","pubTime":"2026-10-06 05:20","pubTimestamp":1791235226,"startTime":"0","endTime":"0","summary":"Jefferies, TD Cowen, Leerink Partners and Stifel are acting as the joint book-running managers for the proposed offering. Published first on TheFly...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-250m-share-spot-secondary-re-offered-at-85-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-250m-share-spot-secondary-re-offered-at-85-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}